The estimated Net Worth of Gregory Norden is at least $18.5 Milion dollars as of 6 May 2024. Mr. Norden owns over 41,133 units of Zoetis Inc stock worth over $16,823,994 and over the last 12 years he sold ZTS stock worth over $1,360,615. In addition, he makes $355,000 as Independent Director at Zoetis Inc.
Gregory has made over 17 trades of the Zoetis Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 41,133 units of ZTS stock worth $7,814,859 on 6 May 2024.
The largest trade he's ever made was exercising 41,133 units of Zoetis Inc stock on 6 May 2024 worth over $7,814,859. On average, Gregory trades about 2,170 units every 68 days since 2013. As of 6 May 2024 he still owns at least 88,552 units of Zoetis Inc stock.
You can see the complete history of Mr. Norden stock trades at the bottom of the page.
Gregory Norden is Independent Director of the Company. Prior to his role as Chief Financial Officer of Wyeth, Mr. Norden held various senior positions with Wyeth Pharmaceuticals and American Home Products. Prior to his affiliation with Wyeth, Mr. Norden served as Audit Manager at Arthur Andersen & Co. Mr. Norden currently serves on the boards of Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products; NanoString Technologies, a provider of life science tools for translational research and development of molecular diagnostic products; Royalty Pharma, a leader in the acquisition of revenue-producing intellectual property; and Univision, the leading media company serving Hispanic America. Mr. Norden is a former director of Welch Allyn, where he served until 2015; Lumara Health, where he served until 2014; and Human Genome Sciences, Inc., where he served until 2012. In addition, Mr. Norden is the Managing Director of G9 Capital Group LLC, which invests in early stage ventures and provides corporate finance advisory services. Mr. Norden’s background in finance and experience as a senior executive in the global healthcare and pharmaceutical industries, along with his public company board experience, make him a valuable member of our Board.
As the Independent Director of Zoetis Inc, the total compensation of Gregory Norden at Zoetis Inc is $355,000. There are 8 executives at Zoetis Inc getting paid more, with Glenn David having the highest compensation of $3,672,350.
Gregory Norden is 62, he's been the Independent Director of Zoetis Inc since 2013. There are 7 older and 15 younger executives at Zoetis Inc. The oldest executive at Zoetis Inc is William Steere, 83, who is the Independent Director.
Gregory's mailing address filed with the SEC is C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK, NY, 10022.
Over the last 12 years, insiders at Zoetis Inc have traded over $876,669,659 worth of Zoetis Inc stock and bought 1,602,140 units worth $77,083,975 . The most active insiders traders include Square Capital Management, ..., Frank A Damelio a Michael B Mccallister. On average, Zoetis Inc executives and independent directors trade stock every 14 days with the average trade being worth of $14,414,921. The most recent stock trade was executed by Soria Ester Banque on 31 July 2024, trading 895 units of ZTS stock currently worth $170,041.
Zoetis Inc. is an American drug company, the worlds largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the worlds largest drug maker, but with Pfizers spinoff of its 83% interest in the firm it is now a completely independent company.
Zoetis Inc executives and other stock owners filed with the SEC include: